Profile of pomalidomide and its potential in the treatment of myelofibrosis

Myelofibrosis, a Philadelphia-negative myeloproliferative neoplasm, is in a new treatment era after the discovery of the JAK2V617F mutation in 2005. JAK inhibitors boast improvements in disease-related symptoms, splenomegaly, and overall survival; however, treatment of myelofibrosis remains a challe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gowin, Krisstina L, Mesa, Ruben A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397931/
https://www.ncbi.nlm.nih.gov/pubmed/25897239
http://dx.doi.org/10.2147/TCRM.S69211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397931/
https://www.ncbi.nlm.nih.gov/pubmed/25897239
http://dx.doi.org/10.2147/TCRM.S69211

Ejemplares similares